Previous 10 | Next 10 |
Alcon (NYSE: ALC) and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) has announced entry into a definitive merger agreement where Alcon will acquire Aerie. Alcon will add commercial products Rocklatan and Rhopressa and a pipeline of several clinical and preclinical o...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock.com Aerie Pharmaceuticals (NASDAQ: AERI ) stock is rising higher on Tuesday following news of an acquisition deal with Alcon (NYSE: ALC ). Alcon is agreeing to acquire Aerie Pharma...
BTIG says that the decision by Swiss eye care company Alcon ( NYSE: ALC ) to acquire U.S.-based Aerie Pharmaceuticals, Inc. ( AERI ) “makes a lot of sense” as the former seeks to expand in glaucoma, a common eye condition that can lead to vision loss. ALC i...
Builds on Alcon’s existing commercial expertise in the estimated $20 billion global ophthalmic pharmaceutical segment 1 Adds Rocklatan ® and Rhopressa ® , and a pipeline of several clinical and preclinical ophthalmic pharmaceutical produc...
Kahn Brothers' 13F portfolio value decreased from ~$788M to ~$743M this quarter. New York Community Bancorp, Citigroup, VOXX International, and ViewRay were increased while decreasing Patterson-UTI Energy during the quarter. The portfolio continues to be very concentrated with the...
Societe Generale has downgraded Alcon ( NYSE: ALC ) to hold from buy as the eye care company's immunity to macro headwinds is declining. The firm has a price target of CHF73.6 (~9% upside based on Thursday's close on the SIX Swiss Exchange). Analyst Delphine Le Louet s...
Alcon Inc. (ALC) Q2 2022 Results Conference Call August 10, 2022 08:00 AM ET Company Participants Dan Cravens - VP and Global Head IR David Endicott - CEO Tim Stonesifer - CFO Conference Call Participants Zach Weiner - Jeffries Chris Cooley - Step...
Alcon press release ( NYSE: ALC ): Q2 Non-GAAP EPS of $0.63 beats by $0.07 . Revenue of $2.2B (+5.3% Y/Y) in-line. FY22 Guidance: Net Sales of $8.6B-$8.8B from prior outlook of $8.7 to $8.9 billion vs. consensus of $8.84B Core EPS of $2.20-$2.30 from prior ...
Strong second quarter sales of $2.2 billion, up 5%, or 10% constant currency (cc) Second quarter earnings of $0.30 per diluted share, down 3%, or up 34% cc Second quarter core earnings of $0.63 per diluted share, up 13%, or 30% cc Updated 2022 full year outlo...
Benefit corporations are a new form of business and increasing in number on the market. Similar to ESG metrics, these companies often take it many steps further in regards to positivity. The business structure allows some profits to be syphoned away towards beneficial endeavors, w...
News, Short Squeeze, Breakout and More Instantly...
Combined vitreoretinal-cataract system (VCS) and standalone cataract system (CS) are cleared for use in the U.S. New, proprietary technologies designed to deliver transformative surgical innovation Alcon to immediately begin collecting real-world user experience in the U.S. prior ...
2024-06-09 17:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Shares of Alcon Inc. (NYSE: ALC) traded at a new 52-week high today and are currently trading at $91.69. So far today, approximately 136.09k shares have been exchanged, as compared to an average 30-day volume of 907.93k shares. Alcon Inc., an eye care company, researches, develops, manufactur...